Drugs in tuberculosis and leprosy

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Tuberculosis (TB) remains a global health threat with approximately 25% of the world's population infected with latent tuberculosis infection (LTBI). Approximately 10% of these patients will develop active TB. Both TB and leprosy are known for their infectious and contagious nature and with increasing resistance patterns emerging and treatment regimens requiring a combination of products (with variable toxicity profiles, drug–drug interactions, and treatment outcomes) to combat the resistance. In this chapter, we review the 2018 literature regarding the adverse effects of medications commonly used in TB and leprosy: aminoglycosides, bedaquiline, carbapenems, clofazimine, cycloserine, dapsone, ethambutol, fluoroquinolones, isoniazid, linezolid, macrolides, pyrazinamide, para-aminosalicylic acid, polypeptides, rifamycins, terizidone, and thiacetazone.

Original languageEnglish
Title of host publicationSide Effects of Drugs Annual
EditorsSidhartha D. Ray
PublisherElsevier B.V.
Pages321-338
Number of pages18
ISBN (Print)9780128171639
DOIs
StatePublished - 2019

Publication series

NameSide Effects of Drugs Annual
Volume41
ISSN (Print)0378-6080

    Fingerprint

Keywords

  • Adverse effects
  • Ethambutol
  • Isoniazid
  • Leprosy
  • Pyrazinamide
  • Rifamycins
  • Side effect
  • Tuberculosis

Cite this

Ramanathan, M. R., Howell, C. K., & Sanders, J. M. (2019). Drugs in tuberculosis and leprosy. In S. D. Ray (Ed.), Side Effects of Drugs Annual (pp. 321-338). (Side Effects of Drugs Annual; Vol. 41). Elsevier B.V.. https://doi.org/10.1016/bs.seda.2019.08.010